Abstract 4051
Background
Pyropheophorbide-a (Pyro) is a highly promising photosensitizer for tumor photodynamic therapy (PDT), while its very limited tumor-accumulation ability seriously restricts its clinically applications. Higher accumulation of photosensitizers are very important for the treatment of deeply seated and larger tumors. Conjugation of Pyro with tumor homing peptide ligands could be a very useful strategy to optimize the physical properties of Pyro. Herein, we reported our studies on the conjugation of Pyro with a cyclic cRGDfK (cRGD) peptide, an integrin binding sequence, with the aim to development a highly tumor specific photosensitizers for PDT application.
Methods
In order to further reduce the non-specific uptake and thus reduce the background distribution of the conjugates in the normal tissues, we opted to add a highly hydrophilic polyethylene glycol (PEG) chain and an extra strongly hydrophilic carboxylic acid group as the linker to avoid the direct connection of strong hydrophobic Pyro macrocycle and cRGD ligand. While hydrophilic modification may affect the PDT activity of photosensitizers via reduction of the membrane attachment. We reported here the synthesis and characterization of these conjugates. Their tumor accumulation ability and photodynamic induced cell killing ability were evaluated through both in vitro cell-base experiment and in vivo distribution and tumor therapy experiments with tumor-bearing mice.
Results
As a result, the synthesized conjugate significantly improved the tumor enrichment and tumor selectivity of Pyro, and abolished the xenograft tumors in the murine model through one time of PDT treatment.
Conclusions
In view of the simple synthesis process and excellent tumor treatment ability, this compound has good clinical application potential.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tianjin Union Medical Center.
Funding
Nankai University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3993 - Prophylaxis with Lipegfilgrastim in patients with primary breast cancer receiving dose dense chemotherapy: results from the German NIS NADENS
Presenter: Marion Kiechle
Session: Poster Display session 1
Resources:
Abstract
3471 - Randomized phase 2 trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients.
Presenter: Florian Clatot
Session: Poster Display session 1
Resources:
Abstract
1327 - Simultaneous intravenous fluid infusion to prevent oxaliplatin infusion-related venous pain
Presenter: Stefan Van Ravensteijn
Session: Poster Display session 1
Resources:
Abstract
5004 - Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project.
Presenter: Enrique Aranda Aguilar
Session: Poster Display session 1
Resources:
Abstract
2222 - Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response.
Presenter: Manuel Cobo Dols
Session: Poster Display session 1
Resources:
Abstract
5556 - Consensus on strategies in the management of opioid-induced constipation in cancer patients
Presenter: Regina Girones Sarrio
Session: Poster Display session 1
Resources:
Abstract
3913 - Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Presenter: Yanni Lou
Session: Poster Display session 1
Resources:
Abstract
2208 - A prospective study about the complementary medicine among patients with cancers
Presenter: Wala Ben Kridis
Session: Poster Display session 1
Resources:
Abstract
1082 - Prevalence and management of Potentially Inappropriate Medication use and Potential Omissions in Medication in older cancer patients - the PIM POM study
Presenter: Fianne van Loveren
Session: Poster Display session 1
Resources:
Abstract
1701 - Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer : A randomized controlled trial
Presenter: Wonyoung Choi
Session: Poster Display session 1
Resources:
Abstract